Protein A Resin Market

Market Definition

The protein A resin is a chromatography purification medium used to isolate antibodies, mainly immunoglobulin G (IgG), from complex mixtures. It contains Protein A, a bacterial protein derived from Staphylococcus aureus, which binds specifically to the Fc region of IgG molecules. 

The market includes natural Protein A and recombinant Protein A, which is produced through genetic engineering. It includes agarose-based, glass or silica-based, and organic polymer-based resins, each offering different properties for performance and stability. Key applications are immunoprecipitation and antibody purification in research and manufacturing.

Protein A Resin Market Overview

The global protein A resin market size was valued at USD 1071.5 million in 2024 and is projected to grow from USD 1122.9 million in 2025 to USD 1563.3 million by 2032, exhibiting a CAGR of 4.83% during the forecast period. 

Market growth is fueled by rising demand for protein A chromatography resin in large-scale purification during biologic drug manufacturing. A major trend is the shift toward universal affinity technologies that simplify the purification process. These solutions eliminate the need for custom methods for each protein, reducing development time and operational costs.

Major companies operating in the protein A resin industry are Purolite, Abcam Limited, Cytiva, JSR Life Sciences, LLC, GenScript, Merck KGaA, Protein Ark, Repligen Corporation, Sepax Technologies, Inc., Thermo Fisher Scientific Inc., Sartorius AG, Agilent Technologies, Inc., TransGen Biotech Co., Ltd., Bio-Rad Laboratories, Inc., and Tosoh Bioscience LLC.

Manufacturers are introducing advanced protein A resin products designed for rapid purification to meet the growing demand for speed and efficiency in biologics production. These resins offer high binding capacity and faster flow rates, enabling quicker processing without compromising product quality. 

There is a major focus is on reducing purification cycle times and increasing batch throughput. Companies are also aligning these products with single-use systems to support flexible manufacturing setups.

• In October 2024, Sartorius AG launched Sartobind Rapid A Lab, a high-speed affinity chromatography unit designed to accelerate antibody purification. Featuring the industry's fastest Protein A matrix, it supports benchtop and rapid cycling applications without buffer degassing. It enables up to 100 purification cycles and delivers up to 17 times higher antibody yields compared to traditional resin columns.

Key Highlights:

1. The protein A resin market size was recorded at USD 1071.5 million in 2024.
2. The market is projected to grow at a CAGR of 4.83% from 2025 to 2032.
3. North America held a market share of 34.09% in 2024, with a valuation of USD 365.2 million.
4. The natural protein A segment garnered USD 665.9 million in revenue in 2024.
5. The agarose-based protein segment is expected to reach USD 652.3 million by 2032.
6. The immunoprecipitation segment is projected to generate a revenue of USD 921.9 million by 2032.
7. The pharmaceutical & biopharmaceutical companies segment is expected to reach USD 601.9 million by 2032.
8. Asia Pacific is anticipated to grow at a CAGR of 5.80% over the forecast period.

Market Driver

Rising Demand in Large-Scale Purification Processes During Biologic Manufacturing

The market is driven by the rising demand for Protein A chromatography resins in large-scale purification processes used in biologic manufacturing. Protein A resins offer high selectivity and efficiency in capturing antibodies from complex mixtures, making them essential in downstream processing. 

As biopharmaceutical production expands globally, manufacturers are increasingly investing in and launching products for rapid purification technologies. This increasing adoption is fueling demand for protein A resins and establishing them as a critical component in large-scale biologic manufacturing.

• In June 2024, Repligen Corporation and Ecolab Life Sciences jointly launched the DurA Cycle, a protein A chromatography resin developed for large-scale biologic manufacturing. The product was introduced at BIO 2024 as part of their strategic partnership, aiming to enhance purification efficiency and reduce manufacturing costs for monoclonal antibodies.

Market Challenge

High Cost and Limited Reusability of Protein A Resin in Biologic Manufacturing

A major challenge limiting the expansion of the protein A resin market is the high cost and limited reusability of the resin in large-scale biologic production. Agarose-based protein A resins are expensive to manufacture. 

Their performance declines after repeated use, which increases the cost per purification cycle. This limits adoption, particularly in cost-sensitive and small-scale operations.

To address this challenge, manufacturers are developing resins with higher binding capacity and longer usable life. Some are investing in alternative ligands that lower production costs while maintaining purification performance.

Market Trend

Adoption of Universal Affinity Technologies for Simplifying Purification

The market is witnessing a notable shift toward affinity technologies that support standardized purification for diverse recombinant proteins. New solutions, such as self-cleaving traceless tags and complementary affinity chromatography resins, eliminate the need for protein-specific binding partners. 

These systems allow a single purification process to be applied across multiple protein formats. This improves operational efficiency, reduces development time, and simplifies downstream workflows. The shift is expanding the use of protein A resin technology in both research and commercial bio manufacturing.

• In November 2023, Cytiva launched its Protein Select technology through a new affinity chromatography resin and self-cleaving traceless tag system. The innovation enables purification of any recombinant protein without residual tags, offering a simplified solution from research to large-scale bioprocessing.

Protein A Resin Market Report Snapshot

Segmentation	Details
By Type	Natural Protein A, Recombinant Protein A
By Product	Agarose-based Protein, Glass or Silica-based Protein, Organic Polymer-based Protein
By Application	Immunoprecipitation, Antibody Purification
By End User	Pharmaceutical & Biopharmaceutical Companies, Academic & Research Institutes, Others
By Region	North America: U.S., Canada, Mexico
	Europe: France, UK, Spain, Germany, Italy, Russia, Rest of Europe
	Asia-Pacific: China, Japan, India, Australia, ASEAN, South Korea, Rest of Asia-Pacific
	Middle East & Africa: Turkey, U.A.E., Saudi Arabia, South Africa, Rest of Middle East & Africa
	South America: Brazil, Argentina, Rest of South America

 Market Segmentation

• By Type (Natural Protein A and Recombinant Protein A): The natural protein A segment earned USD 665.9 million in 2024 due to its high binding affinity and widespread use in legacy purification platforms.
• By Product (Agarose-based Protein, Glass or Silica-based Protein, and Organic Polymer-based Protein): The agarose-based protein segment held a share of 42.17% in 2024, mainly due to its superior flow properties and compatibility with high-capacity purification systems.
• By Application (Immunoprecipitation and Antibody Purification): The immunoprecipitation segment is projected to reach USD 921.9 million by 2032, owing to increased use in academic and diagnostic research involving protein interaction studies.
• By End User (Pharmaceutical & Biopharmaceutical Companies, Academic & Research Institutes, and Others): The pharmaceutical & biopharmaceutical companies segment is projected to reach USD 601.9 million by 2032, propelled by the growing demand for monoclonal antibody production and large-scale bioprocessing.

Protein A Resin Market Regional Analysis

Based on region, the global market has been classified into North America, Europe, Asia Pacific, Middle East & Africa, and South America.

North America protein A resin market share stood at 34.09% in 2024, valued at USD 365.2 million. This dominance is reinforced by the rising investment to expand biologics manufacturing capacity. Biopharmaceutical companies across the region are scaling their production facilities for therapeutic proteins. 

These expansions require a high volume of protein A resin for downstream purification. Development of advanced biologics plants is further supported by government funding, private sector capital, and partnerships between companies. This sustained investment is contributing to the high demand for protein A chromatography resins in the region.

• In June 2025, UCB announced a USD 5 billion investment to build a new biologics manufacturing facility in the U.S. The project aims to support growing demand, create 300 high-skilled jobs, and strengthen U.S.-based CMO partnerships. This expansion reinforces UCB’s commitment to innovation, supply chain resilience, and long-term U.S. growth.

The Asia-Pacific protein A resin industry is poised to grow at a CAGR of 5.80% over the forecast period. This growth is stimulated by the rising demand for protein A resin in antibody drug purification. Countries such as China, India, and Japan are increasing biologics manufacturing, particularly for biosimilar and antibody-based therapies. 

Companies across the region are launching new protein A resin products designed for high-yield antibody purification. These product innovations are accelerating regional market growth.

• In September 2024, JSR Life Sciences launched Amsphere A+, a protein A resin for antibody drug purification. The resin features a protein ligand and polymer technology, offering alkali stability, higher binding capacity, and pressure-flow performance to enhance manufacturing efficiency.

Regulatory Frameworks

• In the U.S., protein A Resin used in biologics manufacturing is regulated by the U.S. Food and Drug Administration (FDA) under current Good Manufacturing Practices (cGMP) outlined in 21 CFR Parts 210 and 211, which apply to the production of pharmaceutical-grade materials.
• In China, the National Medical Products Administration (NMPA) regulates protein A Resin under its Drug Administration Law, and manufacturers must meet GMP standards for raw materials used in therapeutic antibody production.
• In Japan, the Ministry of Health, Labour and Welfare (MHLW) enforces GMP requirements based on the Pharmaceutical and Medical Device Act, which includes materials such as protein A Resin used in biopharmaceutical production.

Competitive Landscape

Key players in the protein A resin market are focusing on innovation and strategic partnerships to strengthen their market position. Many manufacturers are developing high-capacity resins with improved binding efficiency and longer operational life to meet the demands of large-scale antibody purification. 

Companies are entering partnerships with biopharmaceutical firms and research institutions to co-develop customized purification platforms. These collaborations aim to accelerate product development and enable faster adoption of next-generation chromatography technologies. 

Some players are also investing in integrated production systems and continuous processing solutions to support flexible manufacturing.

• In February 2024, Repligen and Purolite launched Praesto CH1, a novel agarose-based affinity resin designed for purifying specialized monoclonal antibodies such as recombinant antibody fragments. The product is the result of a multi-year strategic partnership that combines Purolite’s manufacturing process with Repligen’s ligand technology to address challenges in specialized mAb purification.

List of Key Companies in Protein A Resin Market:

• Purolite
• Abcam Limited
• Cytiva
• JSR Life Sciences, LLC
• GenScript
• Merck KGaA
• Protein Ark
• Repligen Corporation
• Sepax Technologies, Inc.
• Thermo Fisher Scientific Inc.
• Sartorius AG
• Agilent Technologies, Inc.
• TransGen Biotech Co., Ltd.
• Bio-Rad Laboratories, Inc.
• Tosoh Bioscience LLC

Recent Developments (Product Launch)

• In April 2024, Welch Materials launched protein A Tanrose 4FF, an agarose-based high-performance affinity chromatography resin designed for monoclonal antibody purification. The product features a redesigned, alkaline-resistant protein A ligand and a high-flow agarose matrix offering improved rigidity, hydrophilicity, and pressure resistance.